Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000318 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
A Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 1
- Study location
NCT00000318: Completed Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000318 is a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 202 participants, below the 1,518-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000318, a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (1)
Connecticut
- APT Residential Services Division - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 1994-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00000318 record still lists
NCT00000318 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 1,518-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000318 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00000318 about?
NCT00000318 is a clinical study titled "Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1". The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.
What is the current status of trial NCT00000318?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 1994-12. Estimated completion is 2007-08.
What conditions does trial NCT00000318 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders.
What interventions are being tested in trial NCT00000318?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000318?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000318 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000318's enrollment target sits among peer trials
202 21st of 58 higher than 38 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
A Laboratory Model for Heroin Abuse Medications - 8
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia